/EMMA
EMMA Stock - Emmaus Life Sciences, Inc.
Healthcare|BiotechnologyOTC
$0.01-9.09%
$0.00 (-9.09%) • Dec 19
37
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.8
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EMMA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.01 – $0.01
TARGET (TP)$0.01
STOP LOSS$0.01
RISK/REWARD1:NaN
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta9.20
52W High$0.05
52W Low$0.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $16.65M | $29.60M | $18.39M | $20.61M | $23.17M |
| Gross Profit | $15.45M | $28.25M | $15.80M | $17.30M | $20.92M |
| Gross Margin | 92.8% | 95.5% | 85.9% | 83.9% | 90.3% |
| Operating Income | $-1,894,000 | $3.54M | $-6,586,000 | $-6,128,000 | $-32,000 |
| Net Income | $-6,453,000 | $-3,733,000 | $-10,625,000 | $-15,946,000 | $1.35M |
| Net Margin | -38.7% | -12.6% | -57.8% | -77.4% | 5.8% |
| EPS | $-0.10 | $-0.07 | $-0.21 | $-0.32 | $0.03 |
Company Overview
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
EMMABeat Rate
8%
Last 12 quarters
Avg Surprise
-370.0%
EPS vs Estimate
Beats / Misses
1/10
1 met exactly
Latest EPS
$-0.03
Q4 2025
EPS Surprise History
Q3 24
-33.3%
$0.02vs$0.03
Q3 24
-800.0%
$-0.07vs$0.01
Q3 24
No data
Q4 24
-200.0%
$-0.01vs$0.01
Q2 25
-373.7%
$-0.03vs$0.01
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 13, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | — | $-0.03 | — | — |
Q3 2025 | Aug 14, 2025 | — | $-0.02 | — | — |
Q2 2025 | May 15, 2025 | — | $-0.04 | — | — |
Q2 2025 | Apr 14, 2025 | $0.01 | $-0.03 | -373.7% | ✗ MISS |
Q4 2024 | Nov 19, 2024 | $0.01 | $-0.01 | -200.0% | ✗ MISS |
Q3 2024 | Sep 10, 2024 | — | $-0.07 | — | — |
Q3 2024 | Sep 10, 2024 | $0.01 | $-0.07 | -800.0% | ✗ MISS |
Q3 2024 | Jul 2, 2024 | $0.03 | $0.02 | -33.3% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.04 | $-0.01 | +75.0% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.03 | $-0.03 | 0.0% | = MET |
Q2 2023 | May 15, 2023 | $-0.03 | $-0.07 | -133.3% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $0.16 | $0.01 | -93.8% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.00 | $-0.01 | -200.3% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.01 | $-0.18 | -1900.0% | ✗ MISS |
Q2 2022 | May 13, 2022 | $-0.01 | $-0.03 | -400.0% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $0.05 | $-0.14 | -380.0% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | — | $-0.06 | — | — |
Q3 2021 | Sep 2, 2021 | — | $0.05 | — | — |
Q3 2021 | Sep 1, 2021 | — | $-0.17 | — | — |
Latest News
Loading news...
Frequently Asked Questions about EMMA
What is EMMA's current stock price?
Emmaus Life Sciences, Inc. (EMMA) is currently trading at $0.01 per share. The stock has moved -9.09% today.
What is the analyst price target for EMMA?
No analyst price targets are currently available for this stock.
What sector is Emmaus Life Sciences, Inc. in?
Emmaus Life Sciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is EMMA's market cap?
Emmaus Life Sciences, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does EMMA pay dividends?
No, Emmaus Life Sciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBPTH
Bio-Path Holdings, Inc.
$0.07
Mkt Cap: $0.0B
HXBM
Helix BioMedix, Inc.
$2.70
Mkt Cap: $0.0B
NPHC
Nutra Pharma Corp.
$0.00
Mkt Cap: $0.0B
NRXCF
NeutriSci International Inc.
$0.00
Mkt Cap: $0.0B
ORGS
Orgenesis Inc.
$0.75
Mkt Cap: $0.0B
PHCG
Pure Harvest Corporate Group, Inc.
$0.01
Mkt Cap: $0.0B
SQZB
SQZ Biotechnologies Company
$0.02
Mkt Cap: $0.0B
VIBEF
Vibe Growth Corporation
$0.05
Mkt Cap: $0.0B
VPRO
Viropro Inc.
$0.00
Mkt Cap: $0.0B
YECO
Yulong Eco-Materials Limited
$0.08
Mkt Cap: $0.0B
Explore stocks similar to EMMA for comparison